The Claim
Current analytical methods for quantifying rapamycin in human cerebrospinal fluid have a lower limit of quantification in the range of 10–20 ng/mL, which is too high to reliably detect the expected concentrations of rapamycin in the central nervous system due to its low free fraction in blood, thereby representing a significant methodological limitation for evaluating blood-brain barrier penetration in humans.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
The tools we use to measure rapamycin in the fluid around the brain aren't sensitive enough to catch the tiny amounts that actually get there, so we can't tell if it's really crossing into the brain in people.
See the scientific wording
Current analytical methods for quantifying rapamycin in cerebrospinal fluid have a lower limit of quantification around 10–20 ng/mL, which is insufficient to reliably detect expected brain exposure given the low free fraction of rapamycin in blood, creating a major methodological barrier to assessing blood-brain barrier penetration in humans.
What the research says
1 studyStudy: Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease
The study says it's hard to measure rapamycin in spinal fluid because the tools aren't sensitive enough, which supports the idea that current methods aren't good for detecting how much of the drug reaches the brain.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.